The law offices of frank r. cruz announces investigation of immunitybio, inc. (ibrx) on behalf of investors

Los angeles--(business wire)--the law offices of frank r. cruz announces an investigation of immunitybio, inc. (“immunitybio” or the “company”) (nasdaq: ibrx) on behalf of investors concerning the company's possible violations of federal securities laws. if you are a shareholder who suffered a loss, click here to participate. on may 11, 2023, before the market had opened, immunitybio announced that the fda had rejected the biologics license application for the company's immunotherapy drug, ankt.
IBRX Ratings Summary
IBRX Quant Ranking